Eli Pikarsky

List of Publications by Year in Descending Order

60 papers	7,310 citations	32 h-index	66 g-index
66 ext. papers	9,997 ext. citations	14.4 avg, IF	6.01 L-index

#	Paper	IF	Citations
60	Immunotherapies for hepatocellular carcinoma. *Nature Reviews Clinical Oncology*, **2021**,	19.4	57
59	Aptamer-modified DNA tetrahedra-gated metal-organic framework nanoparticle carriers for enhanced chemotherapy or photodynamic therapy. *Chemical Science*, **2021**, 12, 14473-14483	9.4	10
58	Senolytic elimination of Cox2-expressing senescent cells inhibits the growth of premalignant pancreatic lesions. *Gut*, **2021**,	19.2	5
57	pH- and miRNA-Responsive DNA-Tetrahedra/Metal-Organic Framework Conjugates: Functional Sense-and-Treat Carriers. *ACS Nano*, **2021**, 15, 6645-6657	16.7	21
56	Hepatocellular carcinoma. *Nature Reviews Disease Primers*, **2021**, 7, 6	51.1	563
55	Chronic expression of p16 in the epidermis induces Wnt-mediated hyperplasia and promotes tumor initiation. *Nature Communications*, **2020**, 11, 2711	17.4	19
54	Predicting and affecting response to cancer therapy based on pathway-level biomarkers. *Nature Communications*, **2020**, 11, 3296	17.4	24
53	Germline biallelic Mcm8 variants are associated with early-onset Lynch-like syndrome. *JCI Insight*, **2020**, 5,	9.9	7
52	A single cell atlas of the human liver tumor microenvironment. *Molecular Systems Biology*, **2020**, 16, e9682	12.2	26
51	Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice. *Life Science Alliance*, **2020**, 3,	5.8	1
50	The microbiota programs DNA methylation to control intestinal homeostasis and inflammation. *Nature Microbiology*, **2020**, 5, 610-619	26.6	44
49	Are we ready for targeted therapy combinations in HCC?. *Gut*, **2020**, 69, 613-614	19.2	2
48	Excess of the NF-B p50 subunit generated by the ubiquitin ligase KPC1 suppresses tumors via PD-L1- and chemokines-mediated mechanisms. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 29823-29831	11.5	4
47	The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. *Nature*, **2020**, 586, 133-138	50.4	94
46	Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. *Cancers*, **2020**, 12,	6.6	9
45	VICKZ1 enhances tumor progression and metastasis in lung adenocarcinomas in mice. *Oncogene*, **2019**, 38, 4169-4181	9.2	14
44	The immunology of hepatocellular carcinoma. *Nature Immunology*, **2018**, 19, 222-232	19.1	411

43	Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy. *Cancer Biology and Therapy*, **2018**, 19, 645-648	4.6	5
42	Small Molecules Co-targeting CKI and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. *Cell*, **2018**, 175, 171-185.e25	56.2	68
41	microRNA 193a-5p Regulates Levels of Nucleolar- and Spindle-Associated Protein 1 to Suppress Hepatocarcinogenesis. *Gastroenterology*, **2018**, 155, 1951-1966.e26	13.3	49
40	Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes. *Oncogenesis*, **2018**, 7, 80	6.6	8
39	Immune defects caused by mutations in the ubiquitin system. *Journal of Allergy and Clinical Immunology*, **2017**, 139, 743-753	11.5	8
38	Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS. *Cancer Cell*, **2017**, 31, 771-789.e6	24.3	98
37	Long Noncoding RNA MALAT1 Promotes Hepatocellular Carcinoma Development by SRSF1 Upregulation and mTOR Activation. *Cancer Research*, **2017**, 77, 1155-1167	10.1	194
36	Learning the Roles of the Hepatic Adaptive Immune System in Hepatocellular Carcinoma-Nature's Guide for Successful Cancer Immunotherapy. *Seminars in Liver Disease*, **2017**, 37, 210-218	7.3	3
35	Hepatocellular carcinoma. *Nature Reviews Disease Primers*, **2016**, 2, 16018	51.1	1274
34	Hepatocellular carcinoma repression by TNF-mediated synergistic lethal effect of mitosis defect-induced senescence and cell death sensitization. *Hepatology*, **2016**, 64, 1105-20	11.2	16
33	RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer. *Cell Reports*, **2016**, 14, 1462-1476	10.6	76
32	PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells. *Hepatology*, **2016**, 63, 813-26	11.2	46
31	Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc. *Cell Host and Microbe*, **2016**, 20, 215-25	23.4	301
30	Chronic inflammation induces a novel epigenetic program that is conserved in intestinal adenomas and in colorectal cancer. *Cancer Research*, **2015**, 75, 2120-30	10.1	72
29	KPC1-mediated ubiquitination and proteasomal processing of NF-B1 p105 to p50 restricts tumor growth. *Cell*, **2015**, 161, 333-47	56.2	66
28	Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. *Nature Immunology*, **2015**, 16, 1235-44	19.1	178
27	Animal model studies indicate a candidate biomarker for sorafenib treatment of hepatocellular carcinoma. *Molecular and Cellular Oncology*, **2015**, 2, e968028	1.2	
26	Restoring inflammatory balance as a potential preventive strategy for inflammation induced cancer. *OncoImmunology*, **2015**, 4, e1039764	7.2	3

25	Nonsyndromic Early-Onset Cone-Rod Dystrophy and Limb-Girdle Muscular Dystrophy in a Consanguineous Israeli Family are Caused by Two Independent yet Linked Mutations in ALMS1 and DYSF. *Human Mutation*, **2015**, 36, 836-41	4.7	13
24	Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. *Cancer Discovery*, **2014**, 4, 730-43	24.4	137
23	Adult hepatocytes are generated by self-duplication rather than stem cell differentiation. *Cell Stem Cell*, **2014**, 15, 340-349	18	314
22	Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development. *Rna*, **2014**, 20, 505-15	5.8	63
21	Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 17582-7	11.5	37
20	Vav1 promotes lung cancer growth by instigating tumor-microenvironment cross-talk via growth factor secretion. *Oncotarget*, **2014**, 5, 9214-26	3.3	8
19	Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice. *Hepatology*, **2013**, 58, 363-73	11.2	66
18	Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice. *Hepatology*, **2013**, 58, 1021-30	11.2	54
17	Vav1 fine tunes p53 control of apoptosis versus proliferation in breast cancer. *PLoS ONE*, **2013**, 8, e54321	3.7	26
16	Genome-wide analysis of androgen receptor targets reveals COUP-TF1 as a novel player in human prostate cancer. *PLoS ONE*, **2012**, 7, e46467	3.7	14
15	NF-B in liver cancer: the plot thickens. *Current Topics in Microbiology and Immunology*, **2011**, 349, 185-96	3.3	8
14	Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 2207-12	11.5	93
13	The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice. *Molecular Cancer*, **2010**, 9, 54	42.1	31
12	beta-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor. *PLoS ONE*, **2010**, 5, e9060	3.7	34
11	The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. *PLoS ONE*, **2009**, 4, e6695	3.7	106
10	S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. *Hepatology*, **2009**, 50, 1251-62	11.2	108
9	The haematopoietic specific signal transducer Vav1 is aberrantly expressed in lung cancer and plays a role in tumourigenesis. *Journal of Pathology*, **2009**, 219, 25-34	9.4	49
8	Anti-Leukemia and Multiple Myeloma Selective Activity of CXCR4 Antagonist 4F-Benzoyl-TN14003 Involves Apoptotic Death Pathway.. *Blood*, **2009**, 114, 3857-3857	2.2	1

7	Contradictory functions of NF-kappaB in liver physiology and cancer. *Cancer Letters*, **2008**, 267, 182-8	9.9	53
6	NF-kappaB inhibition: a double-edged sword in cancer?. *European Journal of Cancer*, **2006**, 42, 779-84	7.5	94
5	Inflammation and cancer: is the link as simple as we think?. *Journal of Investigative Dermatology*, **2005**, 124, x-xiv	4.3	68
4	RNA-Binding Protein VICKZ Is Expressed in a Germinal Center Associated Pattern among Lymphoma Subtypes.. *Blood*, **2005**, 106, 1909-1909	2.2	
3	NF-kappaB functions as a tumour promoter in inflammation-associated cancer. *Nature*, **2004**, 431, 461-6	50.4	2066
2	The haematopoietic specific signal transducer Vav1 is expressed in a subset of human neuroblastomas. *Journal of Pathology*, **2003**, 199, 526-33	9.4	58
1	Nuclear factor-kappaB protects the liver against genotoxic stress and functions independently of p53. *Cancer Research*, **2003**, 63, 25-30	10.1	19